Literature DB >> 22727822

Acute behavioural responses to nicotine and nicotine withdrawal syndrome are modified in GABA(B1) knockout mice.

Andrés P Varani1, Lirane Machado Moutinho, Bernhard Bettler, Graciela N Balerio.   

Abstract

Nicotine is the main active component of tobacco, and has both acute and chronic pharmacological effects that can contribute to its abuse potential in humans. The aim of the present study was to evaluate a possible role of GABA(B) receptors in acute and chronic responses to nicotine administration, by comparing GABA(B1) knockout mice and their wild-type littermates. In wild-type mice, acute nicotine administration (0.5, 1, 3 and 6 mg/kg, sc) dose-dependently decreased locomotor activity, and induced antinociceptive responses in the tail-immersion and hot-plate tests. In GABA(B1) knockout mice, the hypolocomotive effect was observed only with the highest dose of nicotine, and the antinociceptive responses in both tests were significantly reduced in GABA(B1) knockout mice compared to their wild-type littermate. Additionally, nicotine elicited anxiolytic- (0.05 mg/kg) and anxiogenic-like (0.8 mg/kg) responses in the elevated plus-maze test in wild-type mice, while selectively the anxiolytic-like effect was abolished in GABA(B1) knockout mice. We further investigated nicotine withdrawal in mice chronically treated with nicotine (25 mg/kg/day, sc). Mecamylamine (1 mg/kg, sc) precipitated several somatic signs of nicotine withdrawal in wild-type mice. However, signs of nicotine withdrawal were missing in GABA(B1) knockout mice. Finally, there was a decreased immunoreactivity of Fos-positive nuclei in the bed nucleus of the stria terminalis, basolateral amygdaloid nucleus and hippocampal dentate gyrus in abstinent wild-type but not in GABA(B1) knockout mice. These results reveal an interaction between the GABA(B) system and the neurochemical systems through which nicotine exerts its acute and long-term effects.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22727822     DOI: 10.1016/j.neuropharm.2012.06.006

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  17 in total

1.  Altered nocifensive behavior in animal models of autism spectrum disorder: The role of the nicotinic cholinergic system.

Authors:  Li Wang; Luis E F Almeida; Margaret Nettleton; Alfia Khaibullina; Sarah Albani; Sayuri Kamimura; Mehdi Nouraie; Zenaide M N Quezado
Journal:  Neuropharmacology       Date:  2016-09-13       Impact factor: 5.250

2.  Influence of nicotine on doxorubicin and cyclophosphamide combination treatment-induced spatial cognitive impairment and anxiety-like behavior in rats.

Authors:  Yoshihisa Kitamura; Erika Kanemoto; Misaki Sugimoto; Ayumi Machida; Yuka Nakamura; Nanami Naito; Hirotaka Kanzaki; Ikuko Miyazaki; Masato Asanuma; Toshiaki Sendo
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2017-01-07       Impact factor: 3.000

3.  Anxiolytic-like and anxiogenic-like effects of nicotine are regulated via diverse action at β2*nicotinic acetylcholine receptors.

Authors:  S M Anderson; D H Brunzell
Journal:  Br J Pharmacol       Date:  2015-03-24       Impact factor: 8.739

Review 4.  Unraveling the neurobiology of nicotine dependence using genetically engineered mice.

Authors:  Astrid K Stoker; Athina Markou
Journal:  Curr Opin Neurobiol       Date:  2013-03-29       Impact factor: 6.627

Review 5.  New mechanisms and perspectives in nicotine withdrawal.

Authors:  K J Jackson; P P Muldoon; M De Biasi; M I Damaj
Journal:  Neuropharmacology       Date:  2014-11-26       Impact factor: 5.250

6.  Attenuation by baclofen of nicotine rewarding properties and nicotine withdrawal manifestations.

Authors:  Andrés P Varani; Ester Aso; Lirane Machado Moutinho; Rafael Maldonado; Graciela N Balerio
Journal:  Psychopharmacology (Berl)       Date:  2014-02-20       Impact factor: 4.530

7.  Chronic sazetidine-A maintains anxiolytic effects and slower weight gain following chronic nicotine without maintaining increased density of nicotinic receptors in rodent brain.

Authors:  G Patrick Hussmann; Kristen E DeDominicis; Jill R Turner; Robert P Yasuda; Jacquelyn Klehm; Patrick A Forcelli; Yingxian Xiao; Janell R Richardson; Niaz Sahibzada; Barry B Wolfe; Jon Lindstrom; Julie A Blendy; Kenneth J Kellar
Journal:  J Neurochem       Date:  2014-02-07       Impact factor: 5.372

8.  Anxiolytic- and antidepressant-like effects of the methadone metabolite 2-ethyl-5-methyl-3,3-diphenyl-1-pyrroline (EMDP).

Authors:  Patrick A Forcelli; Jill R Turner; Bridgin G Lee; Thao T Olson; Teresa Xie; Yingxian Xiao; Julie A Blendy; Kenneth J Kellar
Journal:  Neuropharmacology       Date:  2015-09-11       Impact factor: 5.250

Review 9.  Involvement of glutamatergic and GABAergic systems in nicotine dependence: Implications for novel pharmacotherapies for smoking cessation.

Authors:  Xia Li; Svetlana Semenova; Manoranjan S D'Souza; Astrid K Stoker; Athina Markou
Journal:  Neuropharmacology       Date:  2013-06-07       Impact factor: 5.250

Review 10.  Role of corticotropin-releasing factor in alcohol and nicotine addiction.

Authors:  Sierra Simpson; Kokila Shankar; Adam Kimbrough; Olivier George
Journal:  Brain Res       Date:  2020-04-21       Impact factor: 3.252

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.